Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity
Open Access
- 22 March 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (7) , 925-928
Abstract
The enhanced-sensitivity Trofile assay (TF-ES; Monogram Biosciences) was used to retest coreceptor tropism samples from 4 different cohorts of HIV-1–infected patients. Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts.Keywords
This publication has 10 references indexed in Scilit:
- Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 InfectionThe Journal of Infectious Diseases, 2010
- Response to Vicriviroc in Treatment‐Experienced Subjects, as Determined by an Enhanced‐Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211The Journal of Infectious Diseases, 2009
- A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1The Journal of Infectious Diseases, 2009
- Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences, 2008
- Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5Journal of the International AIDS Society, 2008
- Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211The Journal of Infectious Diseases, 2007
- Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor TropismAntimicrobial Agents and Chemotherapy, 2007
- Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDSAnnals of Internal Medicine, 1993